Cayman Islands vs India: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Cayman Islands
0.2%
in 2024
India
0.2%
in 2024
Cayman Islands rank
78th
India rank
78th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Cayman Islands
- India
How they compare
Cayman Islands currently reports 0.2% against 0.2% in India, a difference of 0.0%.
Across all 10 years both countries report, India has been ahead every year.
Cayman Islands ranks 78th and India ranks 78th of 215 countries.
India has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cayman Islands | India | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.4% | 0.1% | India |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Cayman Islands or India?
- Cayman Islands, at 0.2% against 0.2% in India as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Cayman Islands and India?
- 0.0%, with Cayman Islands ahead.
- How many years of comparable data are there for Cayman Islands and India?
- 10 years are reported by both, from 2015 to 2024.
- How do Cayman Islands and India rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Cayman Islands ranks 78th and India ranks 78th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.